Salvat participated in the CPhI North America Congress, which annually gathers the most important companies of North America. This year it was held in Chicago, where we held many meetings with other pharmaceutical companies to explore opportunities that allow us to continue developing our activity in the United States.
Salvat’s News and Press kit
Salvat at a glance
What are we doing right now
Salvat and Pharmaloop participated in the CPhI Worldwide Congress, which annually gathers the most important companies in the pharmaceutical world. This year it was held in Madrid, where both companies had the opportunity to hold many meetings with other pharmaceutical companies to explore opportunities that allow us to increase our activities internationally.
Laboratorios Salvat has participated in the consortium created for the development of the INDREYE research project “Innovative solutions for the treatment and diagnosis of dry eye syndrome” funded by the Spanish National Program of Public-Private Cooperation, subprogram INNPACTO, 2012 call. This program is co-financed by the European Union through the European regional development fund (ERDF/FEDER).
On July 26, 2018, the Spanish Ministry of Industry, Commerce and Tourism, through the General Secretariat of Industry and Small and Medium Enterprises resolved to grant Laboratorios Salvat its classification within Group A: Companies with significant research activity with own pharmaceutical production plant or its own basic or preclinical R & D center, with the […]
On August 30th 2018, the enrolment of patients into the CIFLOTEX clinical trial was completed. This study has been carried out in 45 US centers, and 493 patients suffering from Acute Otitis Externa (AOE) have been included. The objective of the study is to assess the efficacy and safety of our combination of Ciprofloxacin + […]